RainDrop System Unlocks Power of Trovagene's Urine-Based Mutation Detection Technology

 RainDrop System Unlocks Power of Trovagene's Urine-Based Mutation Detection
                                  Technology

Digital PCR system adoption helps create ultra-sensitive cell-free DNA assay

PR Newswire

SAN DIEGO and BILLERICA, Mass., July 29, 2013

SAN DIEGO and BILLERICA, Mass., July 29, 2013 /PRNewswire/ -- Trovagene, Inc.
(NASDAQ: TROV) and RainDance Technologies announced today that Trovagene has
adopted RainDance's RainDrop^TM Digital PCR System for research and
development, and for eventual use in the Trovagene CLIA laboratory. Trovagene
has also announced successful development of a cell-free DNA mutation assay
leveraging the RainDrop platform.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"Trovagene's DNA isolation and assay development is at the forefront of
non-invasive, cell-free cancer mutation detection and monitoring,"said Roopom
Banerjee, president and CEO of RainDance. "Utilizing our RainDrop Digital PCR
System,they have addressed a critical need by enabling the use of a
non-invasive, systemic specimen. This technology platform allows better
assessment of tumor dynamics within an individual sample."

The automated RainDrop System allows for a hundred-fold increase in the amount
of DNA that can be analyzed for cancer mutation detection, increasing
sensitivity and the ability to find rare mutations. It can analyze up to 10
million pico-liter sized droplets in a single assay, vastly improving the
probability that low-level mutations will be detected. RainDance's digital PCR
approach also enables quantification of the relative amounts of mutated DNA in
a sample.

Understanding the genomic changes that define a patient's tumor can lead to
clinically actionable information before, during and after therapy. The
ability to non-invasively detect and monitor oncogenic mutations and genomic
variations, as well as markers for resistance, may improve the overall
management of cancer and lead to improved outcomes.

"Trovagene's goal is to help improve detection and monitoring of cancer
patients undergoing treatment, particularly those with metastatic cancers,"
stated Mark Erlander, chief scientific officer of Trovagene. "Analyzing the
large amounts of DNA present in urine requires a platform capable of handling
hundreds of thousands, if not millions, of reactions. The RainDrop System is
ideally suited for this task and enables Trovagene technology to be even more
sensitive."

Trovagene evaluated several platforms before purchasing RainDance's RainDrop
Digital PCR System. "The high level of sensitivity and workflow improvements
made it a clear, cost-effective choice for detecting and quantifying singular
oncogene mutations from cell-free DNA," said Erlander.

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented
technology for the detection of cell-free DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that can be
isolated and detected from urine. Trovagene has a strong intellectual property
asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and
European patent applications and issued patents that cover testing for HPV and
other infectious diseases, cancer, transplantation, prenatal and genetic
testing.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or fourth party payer reimbursement; limited sales
and marketing efforts and dependence upon fourth parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2012 and other periodic reports filed with the
Securities and Exchange Commission.

About RainDance Technologies
RainDance Technologies is a leading life sciences company developing
innovative products that enable more accurate, reliable, cost-effective and
early detection of disease and predisposition risk in order to improve human
healthcare. Today, RainDance is focused on better healthcare outcomes and
lowering costs for the research, diagnosis and treatment of cancers and
inherited diseases. The company's innovative RainStormâ„¢ digital droplet
technology powers next-generation sequencing and genetic testing systems that
deliver dramatically superior performance, cost, interpretability, and ease of
use. RainDance systems are used routinely in major academic research
institutions, clinical genetics laboratories, and hospitals around the world.
Based in Billerica, Massachusetts, the company supports customers through its
international sales and service operations as well as a global network of
distributors and commercial service providers. For more information, please
visit www.RainDanceTech.com.

The RainDrop System is for Research Use Only; not for use in diagnostic
procedures.

RainDance Technologies, the RainDance Technologies logo, RainDrop and
RainStorm are trademarks of RainDance Technologies, Inc. All other brands may
be trademarks of their respective holders.

Contacts:
Trovagene, Inc.         RainDance Technologies, Inc.
Amy Caterina            Colin Sanford
Investor Relations      Director, Corporate Communications
858-952-7593            203-340-2441
acaterina@trovagene.com colin@bioscribe.com

SOURCE Trovagene, Inc.

Website: http://www.trovagene.com